About 12 results found for searched term "Farnesyl Transferase" (0.125 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2804 | LB42708 | Farnesyl Transferase |
| LB42708 is an orally active farnesyltransferase (FTase) inhibitor with IC50 of 0.8, 1.2, and 2.0 nM toward H-ras, N-ras, and K-ras, respectively. | ||
| M7631 | B581 | Farnesyl Transferase |
| B-581 | ||
| B581 is a membrane permeable inhibitor of farnesyltransferase. | ||
| M7661 | BMS-214662 hydrochloride | Farnesyl Transferase |
| BMS-214662 is an orally available, potent and selective inhibitor of farnesyltransferase that reduces Ras prenylation in NF90-8 and ST88-14 sheath tumor (MPNST) cell lines. | ||
| M21382 | FTI-2153 | Farnesyl Transferase |
| FTI-2153 is a potent and highly selective inhibitor of farnesyltransferase (FTase) with an IC50 of 1.4 nM. FTI-2153 effectively inhibits the processing modification of H-Ras protein with an IC50 value of 10 nM, and its inhibitory activity is more than 3000 times that of the processing of Rap1A protein. | ||
| M25466 | Manumycin A | Farnesyl Transferase |
| Manumycin A is a selective, competitive inhibitor of protein farnesyl transferase (FTase) with respect to farnesylpyrophosphate (Ki=1.2 μM), and as a noncompetitive inhibitor with respect to the Ras protein. Manumycin A is also an antibiotic. | ||
| M27907 | CP-609754 | Farnesyl Transferase |
| LNK-754; OSI-754 | ||
| CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC50 for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL. | ||
| M28036 | FGTI-2734 | Farnesyl Transferase |
| FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT-1, respectively. FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors. | ||
| M28935 | YM-53601 free base | Farnesyl Transferase |
| YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo. YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent. YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation. | ||
| M28936 | YM-53601 | Farnesyl Transferase |
| YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo. YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent. YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation. | ||
| M29771 | FGTI-2734 mesylate | Farnesyl Transferase |
| FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT, respectively. FGTI-2734 mesylate can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors. | ||
| M30111 | ABT-100 | Farnesyl Transferase |
| ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity. | ||
| M39139 | Andrastin A | Farnesyl Transferase |
| Andrastin A meroterpenoid compound, is a farnesyltransferase inhibitor. Andrastin A inhibits the efflux of anticancer compounds from multidrug-resistant cancer cells. Andrastin A can be isolated from Penicillium species. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
